From optimism to disillusion about commitment to transparency in the medico-industrial complex
- 1 July 2006
- journal article
- review article
- Published by SAGE Publications in Journal of the Royal Society of Medicine
- Vol. 99 (7), 337-341
- https://doi.org/10.1258/jrsm.99.7.337
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Clinical trial registration: transparency is the watchwordThe Lancet, 2006
- Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation AntipsychoticsAmerican Journal of Psychiatry, 2006
- Open access to industry's clinically relevant dataBMJ, 2004
- In the dark: drug companies should be forced to publish all the results of clinical trials.2004
- Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials.2004
- Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applicationsBMJ, 2003
- Pharmaceutical industry sponsorship and research outcome and quality: systematic reviewBMJ, 2003
- Good publication practice for pharmaceutical companiesCurrent Medical Research and Opinion, 2003
- The uncertainty principle and industry-sponsored researchThe Lancet, 2000
- Study of information submitted by drug companies to licensing authorities.BMJ, 1980